Search

everythinglearnresearchcommunity

for

Search:↓

A user in Poland created a homemade "oral topical minoxidil" using 2% topical minoxidil, propylene glycol, and vodka due to difficulty obtaining oral minoxidil. They shared a recipe and sought feedback, emphasizing caution and safety in dosing.

User asks about topical spironolactone experience. Two studies show it as promising anti-androgen treatment, with 5% cream available on Minoxidilmax website.

The user has been using finasteride and minoxidil since October 2023 and is concerned if a supplement containing L-arginine, L-citrulline, Tongkat Ali, Tribulus terrestris, Avena Sativa, Gingko Biloba, Ginseng, Pyridoxine, Zinc Gluconate, and Saw Palmetto can cause hair loss. They report thicker and denser hair despite ongoing shedding.

Minoxidil isn't effective for OP, who is exploring latanoprost and bimatoprost for hair growth. Users suggest higher concentrations of latanoprost (0.1%) are needed for effectiveness, but they are costly and hard to find.

Users discuss making topical finasteride solutions by dissolving crushed tablets in ethanol and propylene glycol, with concerns about residue affecting effectiveness. They also mention using minoxidil and oral finasteride, noting some hair regrowth and no side effects from topical use.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

The user found success in treating hair loss by using a derm stamp with castor oil, vitamin E oil, and rosemary oil, alongside finasteride. The derm stamp, used every other day at 0.5 mm, significantly improved hair thickness and growth.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

The conversation discusses using oral castor oil as a hair growth stimulant for beard and scalp hair. One user questions its use, noting castor oil is typically a laxative in the Philippines.

Oral minoxidil was ineffective for OP, causing hair loss and unwanted body hair, while topical minoxidil showed significant regrowth. OP is switching to topical minoxidil with glycerin due to scalp issues with propylene glycol.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.

A user noticed increased hair loss and was prescribed Betamethasone dipropionate 0.05% lotion by a dermatologist. Another user suggested changing doctors and asking for finasteride instead.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.

Minoxidil can be effectively delivered through nanoemulsions containing eucalyptol or oleic acid, enhancing its diffusivity and targeting hair follicles. This contradicts the advice against mixing minoxidil with oils in topical formulations.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

White peony root extract is discussed as a potential treatment for hair loss. The conversation questions if anyone has tried it or researched its use in traditional Chinese medicine.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The user is considering combining finasteride and minoxidil tablets into a topical solution that already includes Garnier Fructis stemoxydine and CB0103. They are seeking advice on whether this combination is effective and safe.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

The user is considering storing Fluridil in a different container for easier application and asks if it can be mixed with Minoxidil or if hair styling products will affect its potency. They also inquire about the order and timing of applying these hair loss treatments.

Hair loss discussion includes topical latanoprost and melatonin. Users share regimens and products used for treatment.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

A 25-year-old male is experiencing positive temple regrowth after using 1 mg oral finasteride daily and a custom topical solution from Musely containing minoxidil, dutasteride, tretinoin, ketoconazole, and hydrocortisone. He is considering adding dermarolling to enhance results, while others share their experiences and suggestions for hair regrowth treatments.